Neumora Therapeutics
NMRA
114 hedge funds and large institutions have $137M invested in Neumora Therapeutics in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 10 closing their positions.
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
48% more call options, than puts
Call options by funds: $2.68M | Put options by funds: $1.81M
22% more capital invested
Capital invested by funds: $113M → $137M (+$24.6M)
12% more funds holding
Funds holding: 102 → 114 (+12)
4.46% more ownership
Funds ownership: 37.67% → 42.13% (+4.5%)
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$13.2M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$5.72M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.59M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.12M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.96M |
| 2 |
Millennium Management
New York
|
-$2.23M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.37M |
| 4 |
Jane Street
New York
|
-$988K |
| 5 |
SoftBank Group
Tokyo,
Japan
|
-$880K |
NMRA Hedge Fund Activity: Q1 2026 in Review
114 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2026, worth a combined $137M — up 22% from $113M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NMRA positions and 10 closed out — a net gain of 14 holders — while 34 added to existing stakes and 32 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $13.2M. The largest seller was Point72 Asset Management, cutting an estimated $7.96M.
- 114 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2026, up from 102 in Q4 2025.
- Funds reported $137M of Neumora Therapeutics stock for Q1 2026, up 22% quarter-over-quarter.
- 24 funds opened new Neumora Therapeutics positions in Q1 2026 and 10 closed out, a net change of +14 holders.
- The largest Neumora Therapeutics buyer in Q1 2026 was Perceptive Advisors, an estimated $13.2M added.
- The largest Neumora Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $7.96M sold.
Based on aggregated 13F filings for Q1 2026.